↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Lisata Therapeutics$LSTA · filed: saw revenue fall 83.0% in FY2025 to $0MRotting at the dockNext year $0.0M–$0.1M sealedCheck ▾Close ▴
What Lisata Therapeutics filed
Saw revenue fall 83.0% in FY2025 to $0 million, operating margin -10711% against a -3.8% median for pharmaceutical preparations, equity 83.7% of assets. Every figure links to the filing it came from on Lisata Therapeutics’s card. Rotting at the dock: four or more warning signs.
What the house said in advance
Revenue for the fiscal year after 2025-12-31 between $0.0M and $0.1M, an 80% range sealed on 20 Sept 2026 · receipt #28cfba · graded in public by the revenue in Lisata Therapeutics’s next annual report.
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
Rare new biotech buyer at **$4.00** cash plus CVR, in a quarter with **41%** fewer deals and distressed-asset pricing.
$4.00
per share in cash
3.4%
discount to the cash component
$12 million
in cash at last quarter-end
$8.3 million
in the September quarter and carried a market capitalization…
Kuva Labs Inc. commenced its tender offer for Lisata Therapeutics at $4.00 per share in cash, plus one non-tradeable contingent value right per share. The offer opened this week with standard twenty-business-day mechanics. Lisata's board unanimously recommended acceptance. The stock closed yesterday at $3.87, a 3.4% discount to the cash component.
Lisata brought one mid-stage pancreatic cancer asset — certepetide, a LDLR-targeting peptide designed to enhance chemotherapy delivery — and roughly $12 million in cash at last quarter-end. The company had burned through $8.3 million in the September quarter and carried a market capitalization below $40 million before the deal announcement in late March. Kuva, a private oncology-focused biotech backed by a single-family office in Southern California, disclosed no prior portfolio holdings. The contingent value right ties to unspecified regulatory or commercial milestones for certepetide, with payout terms undisclosed in the tender filing. No timeline was given for CVR resolution.
The deal marks the eighth sub-$100 million biotech acquisition since January and one of three with a CVR structure in that cohort. Biotech M&A volume dropped 41% year-over-year in the first quarter, with median deal size falling to $87 million from $310 million in the prior-year period. Kuva's entry as a new buyer is noteworthy in a quarter where nineteen of twenty-three transactions involved repeat acquirers. The $4.00 offer represents a 127% premium to Lisata's sixty-day average before the March announcement, but only 22% above the twelve-month low. Pre-clinical oncology assets with FDA orphan designation typically command 2.5x to 4.0x cash-to-asset multiples in distressed sales; Lisata's certepetide holds orphan status for pancreatic adenocarcinoma.
Allocators should watch for CVR disclosure in the definitive proxy, expected within ten days of tender commencement. If the payout structure ties to Phase III data rather than partnering events, it signals Kuva intends full development and suggests capital availability exceeding $150 million — the rough burn required to reach a pancreatic cancer pivotal readout. Second, monitor whether Kuva files beneficial ownership for other sub-$50 million oncology names in the next ninety days; single-asset acquisitions by new buyers often precede portfolio roll-ups. Third, Lisata's two largest shareholders — a 9.8% holder and a 7.2% holder, both hedge funds — filed no 13D amendments opposing the deal, implying limited competing interest.
Twenty-three biotech companies with market caps below $60 million and single mid-stage assets now trade within 15% of cash value, up from eleven in January.
Branded by POPS4 · proof in 60 seconds
For the principal
If you hold sub-scale biotech, this sets a floor — cash plus CVR at 127% premiums, but only for orphan-designated assets.
For the operator
Track CVR structure in the proxy; if milestone is Phase III, Kuva has serious capital and may build a platform via serial buys.
For the house
We're reviewing the nineteen biotech names under $60M with single assets for similar setups; two already on watchlist for Q3 volatility trades.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.
